Compare ELPC & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ELPC | CYTK |
|---|---|---|
| Founded | 1954 | 1997 |
| Country | Brazil | United States |
| Employees | 3129 | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.6B |
| IPO Year | N/A | 2004 |
| Metric | ELPC | CYTK |
|---|---|---|
| Price | $12.38 | $74.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $89.26 |
| AVG Volume (30 Days) | 333.6K | ★ 2.2M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.53% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $13,368,000.00 |
| Revenue This Year | N/A | $7.37 |
| Revenue Next Year | $12.11 | $310.19 |
| P/E Ratio | $77.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.32 | $29.31 |
| 52 Week High | $13.70 | $80.20 |
| Indicator | ELPC | CYTK |
|---|---|---|
| Relative Strength Index (RSI) | 44.97 | 65.82 |
| Support Level | $12.36 | $58.59 |
| Resistance Level | $13.70 | N/A |
| Average True Range (ATR) | 0.31 | 3.38 |
| MACD | -0.14 | 1.21 |
| Stochastic Oscillator | 4.11 | 71.96 |
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power Sale, Services, and Holding. The majority of its revenue is generated from the Power distribution segment under which it provides public electricity distribution services, being responsible for the operation and maintenance of the distribution infrastructure, as well as providing related services.
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.